Seven Fleet Capital Management LP Invests $6.31 Billion in Dianthus Therapeutics, Inc. $DNTH

Seven Fleet Capital Management LP bought a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the second quarter, HoldingsChannel reports. The fund bought 64,723 shares of the company’s stock, valued at approximately $6,309,198,000. Dianthus Therapeutics accounts for 1.0% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 22nd biggest position.

Other institutional investors have also recently made changes to their positions in the company. ABS Investment Management LLC bought a new position in shares of Dianthus Therapeutics in the second quarter worth approximately $194,960,000. PNC Financial Services Group Inc. increased its stake in Dianthus Therapeutics by 0.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after buying an additional 139 shares in the last quarter. First Horizon Corp bought a new stake in Dianthus Therapeutics during the first quarter valued at about $32,000. Virtus Investment Advisers LLC lifted its position in shares of Dianthus Therapeutics by 7.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock valued at $260,000 after acquiring an additional 416 shares in the last quarter. Finally, EFG International AG purchased a new stake in shares of Dianthus Therapeutics during the second quarter worth about $49,000. Institutional investors own 47.53% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on DNTH. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Truist Financial upped their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Wedbush lifted their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $124.27.

Insider Activity

In other news, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president directly owned 4,000 shares in the company, valued at approximately $362,480. This represents a 86.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Adam M. Veness sold 30,000 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the transaction, the senior vice president owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 287,084 shares of company stock valued at $29,615,923. 3.02% of the stock is currently owned by corporate insiders.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH opened at $110.76 on Thursday. The business’s 50 day moving average price is $102.55 and its 200-day moving average price is $86.52. Dianthus Therapeutics, Inc. has a fifty-two week low of $22.81 and a fifty-two week high of $117.88. The company has a market cap of $6.05 billion, a P/E ratio of -26.69 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. As a group, equities analysts predict that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.